News | February 20, 2022
Syncona completes sale of Gyroscope to Novartis
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
New instrument helps maximize lab productivity and extends FTIR to large, heavy samples
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Subscribe To Our Newsletter & Stay Updated
